- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04875962
A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
May 3, 2021 updated by: UCB Biopharma S.P.R.L.
A Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
The purpose of the study is to evaluate the safety and tolerability after administration of multiple doses and the pharmacokinetics (PK) of single and multiple doses of UCB0599 in healthy study participants and participants with Parkinson's Disease (PD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Long Beach, California, United States, 90806
- Up0077 102
-
-
Florida
-
Bay Harbor Islands, Florida, United States, 33154
- Up0077 103
-
DeLand, Florida, United States, 32720
- Up0077 105
-
-
Georgia
-
Atlanta, Georgia, United States, 30331
- Up0077 107
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48334
- Up0077 101
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Up0077 104
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant must be 40 to 80 years of age inclusive, at the time of signing the informed consent
- Study participant with Parkinson's disease (PD) must have a clinical diagnosis of PD. The following diagnostic criteria must be met: Bradykinesia AND at least ONE of the following: muscular rigidity or resting tremor
- Study participant with PD must have a historic brain image (magnetic resonance imaging (MRI) or computerized tomography (CT) obtained at any point from the time of clinical diagnosis to the time of Screening that does not show any brain abnormalities that could cause symptomatic Parkinsonism
- Study participant must have a Hoehn and Yahr Stage: 1 to 3
- Study participant must be either untreated, or treated with a stable regimen (at least 4 weeks prior to Baseline Visit) of antiparkinsonian drugs and is expected to remain on this regimen for the duration of the study
- Body weight >50 kg (110 lbs) and body mass index (BMI) within the range 18 to 32 kg/m^2 (inclusive)
Exclusion Criteria:
- Study participant has a known hypersensitivity to any components of the study medication or comparative drugs as stated in this protocol
- Study participant has a known relevant allergy, a pre-existing history of a relevant allergic condition, or a predisposition for an allergic reaction (ie, total immunoglobulin E [IgE] value above normal range at Screening); this study participant's inclusion should be discussed with the Medical Monitor
- Study participant has a history of levodopa-induced motor fluctuations or dyskinesia expected to interfere with his/her ability to participate in the study
- Study participant has ongoing significant inflammatory gastrointestinal disorders and/or clinical signs of significant gastrointestinal problems at Screening
- Study participant has a historic brain scan (MRI scan or CT scan) or an MRI scan performed at Screening indicative of a clinically significant abnormality
- Study participant has a diagnosis of a significant Central nervous system (CNS) disease other than PD or history of epilepsy or seizure disorder other than febrile seizures as a child
- Abnormalities in lumbar spine previously known or determined by a screening lumbar x-ray (if conducted)
- History of clinically significant back pain, back pathology, and/or back injury (for example, degenerative disease, spinal deformity, or spinal surgery) that may predispose participant to complications or technical difficulty with lumbar puncture
- Evidence or history of significant active bleeding or coagulation disorder or use of drugs that affect coagulation or platelet function within 14 days prior to lumbar catheter insertion
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
- Study participant has a history or present condition of respiratory or cardiovascular disorders at Screening (eg, cardiac insufficiency, coronary heart disease, uncontrolled hypertension, arrhythmia, tachyarrhythmia, or myocardial infarction) which is considered clinically significant by the Investigator
- Study participant has medical history or current diagnosis of diabetes
- Study participant has clinical significant electrocardiogram (ECG) abnormality at Screening, in the opinion of the Investigator
- Study participant has had prior treatment with an investigational vaccine for PD (including active immunization or passive immunotherapy with monoclonal antibodies)
- Study participant has had prior surgical treatment of PD involving intracranial surgery or implantation of a device (including deep brain stimulation) or duodopa
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 - UCB0599
Participants will be randomized to receive a predefined dosage of UCB0599.
|
Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.
|
Experimental: Cohort 2 - UCB0599
Participants will be randomized to receive a predefined dosage of UCB0599.
|
Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.
|
Placebo Comparator: Cohort 1 - Placebo
Participants will be randomized to receive a predefined dosage of Placebo.
|
Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.
|
Placebo Comparator: Cohort 2 - Placebo
Participants will be randomized to receive a predefined dosage of Placebo.
|
Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-Emergent Adverse Avents (TEAEs) from Baseline to End of Study visit
Time Frame: From Baseline to End of study visit (up to Week 7)
|
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
|
From Baseline to End of study visit (up to Week 7)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed plasma concentration (Cmax) in healthy participants on Day 1
Time Frame: Day 1: Predose up to 12 hours post dose
|
Cmax: Maximum observed plasma concentration
|
Day 1: Predose up to 12 hours post dose
|
Maximum observed plasma concentration (Cmax) in healthy participants on Day 28
Time Frame: Day 28: Predose up to 24 hours post dose
|
Cmax: Maximum observed plasma concentration
|
Day 28: Predose up to 24 hours post dose
|
Time to maximum observed plasma concentration (tmax) in healthy participants on Day 1
Time Frame: Day 1: Predose up to 12 hours post dose
|
Tmax: Time of observed Cmax
|
Day 1: Predose up to 12 hours post dose
|
Time to maximum observed plasma concentration (tmax) in healthy participants on Day 28
Time Frame: Day 28: Predose up to 24 hours post dose
|
Tmax: Time of observed Cmax
|
Day 28: Predose up to 24 hours post dose
|
Area under the concentration - time curve (AUC(0-12h)) from time 0 to 12 hours in healthy participants on Day 1
Time Frame: Day 1: Predose up to 12 hours post dose
|
AUC(0-12h): Area under the curve from time 0 to 12 hours
|
Day 1: Predose up to 12 hours post dose
|
Area under the concentration-time curve for the dosing interval (AUCtau) in healthy participants on Day 28
Time Frame: Day 28: Predose up to 24 hours post dose
|
AUCtau: Area under the concentration-time curve for the dosing interval at steady state
|
Day 28: Predose up to 24 hours post dose
|
Maximum observed plasma concentration (Cmax) in patients on Day 1
Time Frame: Day 1: Predose up to 12 hours post dose
|
Cmax: Maximum observed plasma concentration
|
Day 1: Predose up to 12 hours post dose
|
Maximum observed plasma concentration (Cmax) in patients on Day 28
Time Frame: Day 28: Predose up to 24 hours post dose
|
Cmax: Maximum observed plasma concentration
|
Day 28: Predose up to 24 hours post dose
|
Time to maximum observed plasma concentration (tmax) in patients on Day 1
Time Frame: Day 1: Predose up to 12 hours post dose
|
Tmax: Time of observed Cmax
|
Day 1: Predose up to 12 hours post dose
|
Time to maximum observed plasma concentration (tmax) in patients on Day 28
Time Frame: Day 28: Predose up to 24 hours post dose
|
Tmax: Time of observed Cmax
|
Day 28: Predose up to 24 hours post dose
|
Area under the concentration - time curve (AUC(0-12h)) from time 0 to 12 hours in patients on Day 1
Time Frame: Day 1: Predose up to 12 hours post dose
|
AUC(0-12h): Area under the curve from time 0 to 12 hours
|
Day 1: Predose up to 12 hours post dose
|
Area under the concentration-time curve for the dosing interval (AUCtau) in patients on Day 28
Time Frame: Day 28: Predose up to 24 hours post dose
|
AUCtau: Area under the concentration-time curve for the dosing interval at steady state
|
Day 28: Predose up to 24 hours post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 6, 2019
Primary Completion (Actual)
February 19, 2020
Study Completion (Actual)
February 19, 2020
Study Registration Dates
First Submitted
May 3, 2021
First Submitted That Met QC Criteria
May 3, 2021
First Posted (Actual)
May 6, 2021
Study Record Updates
Last Update Posted (Actual)
May 6, 2021
Last Update Submitted That Met QC Criteria
May 3, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UP0077
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified.
For this reason, data from this trial cannot be shared.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on UCB0599
-
UCB Biopharma SRLEnrolling by invitationParkinson's DiseaseUnited States, Poland, Netherlands, France, Germany, Canada, Italy, Spain, United Kingdom
-
UCB Biopharma SRLActive, not recruitingEarly-stage Parkinson's DiseaseUnited States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
-
UCB Biopharma SRLRecruiting